SureTrader Advertisement PRTC
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 619
Posts 92,709
Boards Moderated 28
Alias Born 09/05/02
160x600 placeholder
European Confidence Firms Despite Political Uncertainty
Businesses and consumers across the European Union became more optimistic about their prospects in May, shrugging off concerns about a rise in nationalism and threats to the integrity of the bloc.
More Top Equities Stories Of The Day
Global Financial Institutions Are in Retreat -- WSJ
Indian Ministries Divide on Apple's Retail Vision
Privacy vs. Law Enforcement: Microsoft's View -- WSJ
ADRs End Mostly Lower; Alibaba, Baidu Trade Actively
Valeant Rejected Joint Takeover Approach From Takeda, TPG
Facebook and Microsoft To Build Fiber Optic Cable Across Atlantic
Few Spinoffs Make a Clean Break -- WSJ
Thermo Fisher Scientific to Buy FEI for $4.2 Billion
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19308 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist